Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors
Strategic alliance significantly expands ongoing multi-year collaboration by granting Turnstone broader access and enhanced benefits at Moffitt IND approval received for a Moffitt-sponsored Phase 1 study of TIDAL-01 in melanoma NEW YORK & TAMPA, Fla.–(BUSINESS WIRE)–#TIL–Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors, and Moffitt Cancer Center … [Read more…]
